NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®

December 15, 2023

https://www.globenewswire.com/news-release/2023/11/13/2779161/35057/en/NGM-Bio-Presents-Positive-Phase-2b-Results-from-the-ALPINE-4-Trial-of-Aldafermin-in-Patients-with-Compensated-Cirrhosis-F4-Due-to-NASH-at-AASLD-The-Liver-Meeting.html

—As previously reported, the ALPINE 4 study met its primary endpoint, with aldafermin 3 mg demonstrating a statistically significant reduction in Enhanced Liver Fibrosis (ELF) score compared to placebo after 48 weeks of treatment—

Read more at globenewswire.com

Related news for (NGM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.